Name | Title | Contact Details |
---|---|---|
Jeffrey Dunifon |
Director and Counsel - Privacy and Data Security | Profile |
Nicole Greene |
Senior Director, Assistant General Counsel - North America | Profile |
Patrick Murphy |
Executive Vice President- Chief Legal Officer | Profile |
Kaare Larson |
Vice President, Intellectual Property | Profile |
Timothy O'Brien |
Vice President, Global Legal Affairs | Profile |
Probed Medical Technologies is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Meditrina, a small startup company located in San Jose, CA, and founded in 2016 developed the Aveta™ hysteroscopy suite which was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids.
To enhance the diagnosis and treatment of cardiovascular disease through the development of innovative optical diagnostic and therapeutic devices.
Restructured under new ownership in 2015, TranS1 has emerged stronger than ever – ready to support a product line that provides a foundation for living well, driven by surgeon innovation. Our impressive team includes experienced R&D, Sales and Professional Education professionals. The TranS1 team is focused on resilient and continuous training of its sales force and physician customers, employing best in class training methods that ultimately benefit patients.